<DOC>
	<DOCNO>NCT02853370</DOCNO>
	<brief_summary>Splenic Marginal Zone Lymphoma ( SMZL ) well-defined low-grade B-cell lymphoma , consider rare neoplasm account 2 % non-Hodgkin 's lymphoma ( NHL ) represent case otherwise unclassifiable chronic lymphoid B-cell cluster differentiation antigen 5 ( CD5 ) -lymphoproliferative disorder . SMZL characterize almost exclusive involvement spleen bone marrow 25 % case disease pursue aggressive course patient die lymphoma progression within 3-4 year . Retrospective study indicate purine analogous achieve high response rate naïve pre-treated patient . Moreover , introduction anti-cluster differentiation antigen 20 ( CD20 ) humanize antibody rituximab , either use alone combination chemotherapy report effective produce rapid clearance neoplastic cell .</brief_summary>
	<brief_title>Bendamustine Rituximab Treatment Splenic Marginal Zone Lymphoma</brief_title>
	<detailed_description>Prospective , multicenter , open-label , phase II study , design determine efficacy safety Chemo-immunotherapy combination bendamustine + rituximab patient splenic marginal zone lymphoma . Study Population : previously untreated ( except splenectomy and/or antiviral therapy Hepatitis C Virus ( HCV ) infection ) symptomatic Splenic Marginal Zone patient . Objectives : evaluation efficacy safety R-Bendamustine symptomatic Splenic Marginal Zone Lymphoma patient . Primary Objective : efficacy R-Bendamustine measure Complete Response rate . Complete response rate define regression normal size CT organomegaly ( spleen , liver , lymph node ) ; normalization blood count evidence circulate clonal cell , evidence minor ( ≤ 5 % ) Bone Marrow ( BM ) infiltration detect immunohistochemistry ( IHC ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Initial diagnosis CD20+ Splenic Marginal Zone Lymphoma morphology confirm histology , cytology , immunophenotype ( chromosomal abnormality quantitative multiplex Polymerase Chain Reaction ( PCR ) short fluorescent fragment ( QMPSF ) optional ) accord World Health Organization ( WHO ) 2008 classification Lymphoma criterion accord recommendation Splenic Lymphoma Group non splenectomized patient . 1 . If patient splenectomised : diagnosis bone marrow biopsy ( histology immunohistochemistry ) , blood ( cytology , immunophenotype ) , chromosomal abnormality QMPSF optional . 2 . If patient splenectomised diagnosis spleen , bone marrow biopsy ( histology immunohistochemistry ) , blood ( cytology , immunophenotype ) chromosomal abnormality QMPSF optional . No previous treatment immunotherapy chemotherapy radiotherapy unless pretreatment mono corticotherapy . Patients require treatment least one follow situation : 1 . Symptomatic SMZL splenectomized patient 1 . Bulky ( arbitrarily define ≥6 cm leave costal margin ) progressive painful splenomegaly , without enlarge lymphoadenopathy , without cytopenia , eligible splenectomy willing splenectomy 2 . One follow symptomatic/progressive cytopenia : Hb &lt; 10 g/dL , Plat &lt; 80.000/mm3 , ANC &lt; 1.000/mm3 , whatever reason ( autoimmune hypersplenism bone marrow infiltration ) eligible splenectomy willing splenectomy 3 . SMZL enlarge lymphoadenopathy involvement extranodal sit without cytopenia 2 . Symptomatic disease SMZL splenectomised patient rapidly raise lymphocyte count , development lymphadenopathy involvement extranodal sit . 3 . SMZL concomitant hepatitis C infection respond relapsed Interferon and/or Ribavirin . Clinically and/or radiologically confirm measurable disease treatment start . Aged ≥ 18 yo time initial diagnosis ≤ 80 yo . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Minimum life expectancy &gt; 6 month . Voluntary sign informed consent performance study relate procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . The following laboratory value screen : 1 . Absolute neutrophil count ( ANC ) ≥1.000/mm3 Platelets ≥100.000/mm3 , unless abnormality relate bone marrow infiltration hypersplenism . 2 . Aspartate transaminase ( AST ) ≤2 x upper limit normal ( ULN ) ; Alanine transaminase ( ALT ) ≤2 x ULN ; total bilirubin ≤1.5 x ULN . 3 . Creatinine clearance ≥ 10 ml/min ( calculate CockcroftGault formula ) Uncontrolled hypertension . Uncontrolled diabetes mellitus defined investigator . Active systemic infection require treatment . Previously know HIV positive serology . Active hepatitis B virus infection ( presence antigen hepatitis B surface ( HBS ) + ; case presence antibody anti hepatitis B core antigen ( HBC ) + anti HBS+ , control organize accord guideline American Association Study Liver Disease ( AASLD ) European Association Study Liver ( EASL ) ) . Active previously untreated HCV infection . Prior history malignancy lymphoma within 3 year ( except complete resection basal cell carcinoma , squamous cell carcinoma skin , situ malignancy ) . Patients previously diagnose prostate cancer eligible ( 1 ) disease T1T2a , N0 , M0 , Gleason score ≤7 , prostate specific antigen ( PSA ) ≤10 ng/mL prior initial therapy , ( 2 ) definitive curative therapy ( ie , prostatectomy radiotherapy ) ≥2 year Day 1 Cycle 1 , ( 3 ) minimum 2 year follow therapy clinical evidence prostate cancer , Prostate Specific Antigen ( PSA ) undetectable underwent prostatectomy &lt; 1 ng/mL undergo prostatectomy . Major surgery within 30 day inclusion study A positive Coombs test without haemolysis autoimmune hemolytic anemia exclusion criterion . Impaired renal function creatinine clearance &lt; 10 ml/min . Severe chronic obstructive pulmonary disease hypoxemia . Medical condition require longterm use ( &gt; 1 month ) systemic corticosteroid . Serious medical psychiatric illness likely interfere participation clinical study . Prior participation another study experimental drug last 4 month . Pregnant currently breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>